Clinical Takeaway
Cannabis use was associated with daily reductions in anxiety, but the effects varied meaningfully depending on whether participants used flower or edible products and the cannabinoid profile (CBD, THC, or THC+CBD combination). These findings suggest that product format and cannabinoid composition both influence how cannabis affects anxiety on a day-to-day basis, which has direct implications for patient counseling and product selection. Clinicians should recognize that not all cannabis products produce equivalent anxiolytic outcomes, and individualized guidance on product type remains an important part of therapeutic cannabis recommendations.
#8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study provides critical longitudinal evidence on how different cannabis product formulations (flower versus edibles) differentially affect anxiety symptom trajectories in real-world conditions, addressing a significant gap between widespread therapeutic use and limited clinical data on product-specific efficacy. Understanding these differential effects is essential for clinicians to provide evidence-based guidance on cannabis selection for anxiety management and to identify which patient populations may benefit from specific formulations. The 30-day daily tracking design offers naturalistic outcome data that can inform clinical decision-making regarding cannabis as an anxiolytic intervention in populations already using it therapeutically.
Quality Gate Alerts:
- Preclinical only
Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
🧠 This longitudinal study provides useful real-world data on how different cannabis product forms may differentially affect anxiety symptoms over time, which is clinically relevant given the widespread self-treatment of anxiety with cannabis. The distinction between flower and edible products is important because they differ in cannabinoid absorption kinetics, onset, and duration, potentially explaining variable therapeutic outcomes that patients report. However, the study’s reliance on participant-selected dosing and product composition, lack of standardized THC:CBD ratios, and absence of validated anxiety measurement scales limits our ability to draw firm mechanistic conclusions or translate findings into specific dosing guidance. The heterogeneity in individual responses—likely driven by genetics, baseline anxiety severity, concurrent medications, and unmeasured confounders—means these aggregate trends may not predict any given patient’s response. Clinically, this work supports a more individualized, product-specific approach to cannabis for anxiety: when patients choose to use cannabis for this indication, discussing their preference for flower versus edibles and monitoring their actual sympt
| |